跳至內容

托維妥單抗

維基百科,自由的百科全書
托維妥單抗
單株抗體
種類?
目標PDGFRA
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號1243266-04-7
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6400H9906N1726O2002S54
摩爾質量144,792.97 g·mol−1

托維妥單抗INN:Tovetumab)是一種抗PDGFRA單株抗體,設計用於治療癌症[1]它由MedImmune開發,並試驗用於膠質母細胞瘤非小細胞肺癌[2]對於該藥物的開發於2013年停止。[3][4]

存卡里

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
  2. ^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. The AAPS Journal. November 2020, 23 (1): 4. PMID 33210183. S2CID 227067803. doi:10.1208/s12248-020-00523-3可免費查閱. 
  3. ^ Tovetumab. AdisInsight. Springer Nature Switzerland AG. [2024-03-01]. (原始內容存檔於2017-11-03). 
  4. ^ Williams R. Discontinued in 2013: oncology drugs. Expert Opinion on Investigational Drugs. January 2015, 24 (1): 95–110. PMID 25315907. S2CID 23390614. doi:10.1517/13543784.2015.971154.